<p>Greenwich LifeSciences, Inc.（納斯達克股票代碼：GLSI - 獲取免費報告）副總裁 Jaye Thompson 在 8 月 12 日星期一進行了一筆交易，購入了 800 股 Greenwich LifeSciences 股票。這些股票的平均購入成本為每股 13.85 美元，總價值為 11,080.00 美元。購買完成後，副總裁現在擁有公司 263,148 股股份，價值約 3,644,599.80 美元。這筆交易已在提交給證券交易委員會的文件中披露，可以通過 SEC 網站查閲。</p>
<p>獲取 <strong>Greenwich LifeSciences</strong> 警報：</p>
<p>Jaye Thompson 最近還進行了以下交易：</p>
<ul>
<li>8 月 2 日星期五，Jaye Thompson 購入了 1,000 股 Greenwich LifeSciences 股票。這些股票的平均購入成本為每股 15.15 美元，交易總額為 15,150.00 美元。</li>
<li>7 月 18 日星期四，Jaye Thompson 購入了 1,000 股 Greenwich LifeSciences 股票。這些股票的平均購入價格為每股 16.00 美元，總價值為 16,000.00 美元。</li>
</ul>
<h2>Greenwich LifeSciences 股票表現</h2>
<p>納斯達克股票代碼 GLSI 週一開盤價為 15.92 美元。Greenwich LifeSciences, Inc.一年內最低價為 7.58 美元，最高價為 21.44 美元。該股市值為 2.0505 億美元，市盈率為-22.11，β係數為 1.61。股票的 50 天移動平均價格為 14.68 美元，200 天移動平均價格為 15.10 美元。</p>
<p>Greenwich LifeSciences（納斯達克股票代碼 GLSI - 獲取免費報告）於 8 月 14 日星期三發佈了其財報。公司報告本季度每股虧損（EPS）為-0.20 美元，符合分析師的一致預期。分析師預計，Greenwich LifeSciences, Inc.本財年每股盈利將達到-0.81 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>HC Wainwright 單獨將 Greenwich LifeSciences 股票的目標價從 36.00 美元上調至 38.00 美元，並在 8 月 23 日星期五的研究報告中給予該公司 “買入” 評級。</p>
<p><strong>查看我們關於 GLSI 的最新研究報告</strong></p>
<h2>機構投資者對 Greenwich LifeSciences 的看法</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了 GLSI 股票。Vanguard Group Inc.在第一季度將其在 Greenwich LifeSciences 的持股增加了 0.6%。Vanguard Group Inc.現在擁有該公司 223,102 股股份，價值 4,449,000 美元，較上一季度增持了 1,420 股。Rhumbline Advisers 在第二季度購入了一份新的 Greenwich LifeSciences 股票，價值約 117,000 美元。最後，紐約梅隆銀行在第二季度買入了一份新的 Greenwich LifeSciences 股票，價值約 264,000 美元。目前有 4.16% 的股份由機構投資者和對沖基金持有。</p>
<h2>關於 Greenwich LifeSciences（獲取免費報告）</h2>
<p>Greenwich LifeSciences, Inc.是一家臨牀階段生物製藥公司，致力於開發針對乳腺癌和其他表達 HER2/neu 的癌症的新型癌症免疫療法。其主要產品候選藥物是 GP2，一種免疫療法，目前正在進行防止先前接受手術的患者乳腺癌復發的 III 期臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五支股票勝過 Greenwich LifeSciences</li>
<li>ESG 股票，投資者應瞭解的內容</li>
<li>3 支被低估的股票，現在太便宜不容忽視</li>
<li>5 個分紅增長投資者的折扣機會</li>
<li>分析師視角：如何使用專家意見</li>
<li>什麼是特別股息？</li>
<li>美光科技：購買 44% 價格下跌的 4 個理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ"/></p>
<p>_這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</p>
<p>→ 拜登的行政命令，民主黨的數字貨幣立法，從貨幣金開始的第一步（從貨幣金開始）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTcx"/></p>
<h2>您現在是否應該投資 1,000 美元購入 Greenwich LifeSciences？</h2>
<p>在考慮購入 Greenwich LifeSciences 之前，您可能希望聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Greenwich LifeSciences 並不在名單上。</p>
<p>儘管分析師目前對 Greenwich LifeSciences 持有 “買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

GLSI

<p>格林威治生命科學公司（NASDAQ：GLSI）副總裁傑伊·湯普森於 8 月 12 日以每股 0.85 美元的價格購買了 800 股，總價為 680.00 美元。交易後，湯普森擁有 263,148 股，價值約 644,599.80 美元。此次購買是在此前以每股 0.15 美元和 0.00 美元的價格分別收購 1,000 股之後進行的。該股票開盤價為 0.92 美元，一年內的價格範圍為 0.58 美元至 1.44 美元。分析師預測財年每股收益為-0.81 美元，而 HC Wainwright 將價格目標上調至 2.00 美元，並給予 “買入” 評級</p>

<p>Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson acquired 800 shares of Greenwich LifeSciences stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $13.85 per share, with a total value of $11,080.00. Following the completion of the purchase, the vice president now owns 263,148 shares in the company, valued at approximately $3,644,599.80. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p>
<div class="lb-trans"><p>Greenwich LifeSciences, Inc.（納斯達克股票代碼：GLSI - 獲取免費報告）副總裁 Jaye Thompson 在 8 月 12 日星期一進行了一筆交易，購入了 800 股 Greenwich LifeSciences 股票。這些股票的平均購入成本為每股 13.85 美元，總價值為 11,080.00 美元。購買完成後，副總裁現在擁有公司 263,148 股股份，價值約 3,644,599.80 美元。這筆交易已在提交給證券交易委員會的文件中披露，可以通過 SEC 網站查閲。</p>
</div><p>Get <strong>Greenwich LifeSciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Greenwich LifeSciences</strong> 警報：</p>
</div><p>Jaye Thompson also recently made the following trade(s):</p>
<ul>
<li>On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The shares were acquired at an average cost of $15.15 per share, for a total transaction of $15,150.00.</li>
<li>On Thursday, July 18th, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $16.00 per share, with a total value of $16,000.00.</li>
</ul>
<div class="lb-trans"><p>Jaye Thompson 最近還進行了以下交易：</p>
<ul>
<li>8 月 2 日星期五，Jaye Thompson 購入了 1,000 股 Greenwich LifeSciences 股票。這些股票的平均購入成本為每股 15.15 美元，交易總額為 15,150.00 美元。</li>
<li>7 月 18 日星期四，Jaye Thompson 購入了 1,000 股 Greenwich LifeSciences 股票。這些股票的平均購入價格為每股 16.00 美元，總價值為 16,000.00 美元。</li>
</ul>
</div><h2>Greenwich LifeSciences Stock Performance</h2>
<div class="lb-trans"><h2>Greenwich LifeSciences 股票表現</h2>
</div><p>NASDAQ:GLSI opened at $15.92 on Monday. Greenwich LifeSciences, Inc. has a one year low of $7.58 and a one year high of $21.44. The stock has a market cap of $205.05 million, a PE ratio of -22.11 and a beta of 1.61. The stock has a 50 day moving average price of $14.68 and a 200 day moving average price of $15.10.</p>
<div class="lb-trans"><p>納斯達克股票代碼 GLSI 週一開盤價為 15.92 美元。Greenwich LifeSciences, Inc.一年內最低價為 7.58 美元，最高價為 21.44 美元。該股市值為 2.0505 億美元，市盈率為-22.11，β係數為 1.61。股票的 50 天移動平均價格為 14.68 美元，200 天移動平均價格為 15.10 美元。</p>
</div><p>Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.20). As a group, analysts predict that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Greenwich LifeSciences（納斯達克股票代碼 GLSI - 獲取免費報告）於 8 月 14 日星期三發佈了其財報。公司報告本季度每股虧損（EPS）為-0.20 美元，符合分析師的一致預期。分析師預計，Greenwich LifeSciences, Inc.本財年每股盈利將達到-0.81 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, HC Wainwright upped their price objective on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 23rd.</p>
<div class="lb-trans"><p>HC Wainwright 單獨將 Greenwich LifeSciences 股票的目標價從 36.00 美元上調至 38.00 美元，並在 8 月 23 日星期五的研究報告中給予該公司 “買入” 評級。</p>
</div><p><strong>View Our Latest Research Report on GLSI</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 GLSI 的最新研究報告</strong></p>
</div><h2>Institutional Investors Weigh In On Greenwich LifeSciences</h2>
<div class="lb-trans"><h2>機構投資者對 Greenwich LifeSciences 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of GLSI. Vanguard Group Inc. boosted its holdings in Greenwich LifeSciences by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company's stock valued at $4,449,000 after purchasing an additional 1,420 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at approximately $117,000. Finally, Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the second quarter valued at approximately $264,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了 GLSI 股票。Vanguard Group Inc.在第一季度將其在 Greenwich LifeSciences 的持股增加了 0.6%。Vanguard Group Inc.現在擁有該公司 223,102 股股份，價值 4,449,000 美元，較上一季度增持了 1,420 股。Rhumbline Advisers 在第二季度購入了一份新的 Greenwich LifeSciences 股票，價值約 117,000 美元。最後，紐約梅隆銀行在第二季度買入了一份新的 Greenwich LifeSciences 股票，價值約 264,000 美元。目前有 4.16% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>About Greenwich LifeSciences (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Greenwich LifeSciences（獲取免費報告）</h2>
</div><p>Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.</p>
<div class="lb-trans"><p>Greenwich LifeSciences, Inc.是一家臨牀階段生物製藥公司，致力於開發針對乳腺癌和其他表達 HER2/neu 的癌症的新型癌症免疫療法。其主要產品候選藥物是 GP2，一種免疫療法，目前正在進行防止先前接受手術的患者乳腺癌復發的 III 期臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Greenwich LifeSciences</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>3 Undervalued Stocks That Are Too Cheap to Ignore Right Now</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>The Analyst Edge: How to Use Expert Opinions</li>
<li>What is a Special Dividend?</li>
<li>Micron Technology: 4 Reasons to Buy the 44% Price Dip</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五支股票勝過 Greenwich LifeSciences</li>
<li>ESG 股票，投資者應瞭解的內容</li>
<li>3 支被低估的股票，現在太便宜不容忽視</li>
<li>5 個分紅增長投資者的折扣機會</li>
<li>分析師視角：如何使用專家意見</li>
<li>什麼是特別股息？</li>
<li>美光科技：購買 44% 價格下跌的 4 個理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=GLSI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p>_這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</p>
</div><p>→ Biden's Executive Order, Dems Digital Money Legislation, First Step To (From Monetary Gold)(Ad)</p>
<div class="lb-trans"><p>→ 拜登的行政命令，民主黨的數字貨幣立法，從貨幣金開始的第一步（從貨幣金開始）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTcx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9571&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Greenwich LifeSciences right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購入 Greenwich LifeSciences？</h2>
</div><p>Before you consider Greenwich LifeSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購入 Greenwich LifeSciences 之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂尖和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Greenwich LifeSciences 並不在名單上。</p>
</div><p>While Greenwich LifeSciences currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管分析師目前對 Greenwich LifeSciences 持有 “買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) 副總裁 Jaye Thompson 購買了 800 股公司股票